PRESS RELEASES

On behalf of the sponsor, Acurx Pharmaceuticals, Altasciences is proud to have successfully completed the clinical conduct, data management, and SAS programming for ACX-362E, a novel, oral antibacterial agent for the treatment of Clostridioides difficile infection (CDI), an acute, serious, potentially life-threatening, intestinal infection.

Altasciences is pleased to be adding Drs. Andrew Gorman and Sylvia West to their team of clinical veterinarians. Both will play key roles in providing clinical care, research, and surgical support, as well as insight into protocol development.

Altasciences is pleased to announce the addition of Dr. Lynne LeSauteur, PhD, to their bioanalytical management team, responsible for the Bioanalytical Services department in the U.S.A. and the Ligand Binding team in Canada.

Altasciences is proud to announce that CEO Chris Perkin has been recognized as a 2019 Red Jacket honoree.

Altasciences announced today that they have been selected by Leidos Health to guide and support the development of RAP-103 peptide as a chemical nerve agent therapeutic on behalf of the Medical CBRN Defense Consortium and funded by the Defense Threat Reduction Agency (DTRA).

Altasciences will provide its full-service solutions, including clinical pharmacology, first-in-human and proof-of-concept trials, program management, medical writing, biostatistics, and data management to support and conduct comprehensive early phase clinical services for WuXi AppTec’s multiple ongoing WIND programs.

Altasciences won in the Most Successful Early Phase Research (Preclinical & Phase I) category at the 2019 Clinical and Research Excellence (CARE) Awards. The award win was announced during a ceremony presented by Ben Nemzer at the Hyatt Regency Boston, US on May 2, 2019.

For the 2019 CRO Leadership Awards, Life Science Leader magazine once again teamed up with Industry Standard Research (ISR) to determine the award recipients.